
Incoming Vascular Medicine Fellow @MassGenBrigham | Internal Medicine PGY3 @thaaIMres | 🇨🇱 & 🇺🇸 | Views are my own
Joined August 2022
- Tweets442
- Following1.5K
- Followers726
- Likes3.3K
Max Guarda, MD retweeted
Congratulations to our Transplant and Hepatobiliary research fellow, Dr. Belén Rivera @MBRiveraMD, on graduating with her Master of Public Health (MPH) from Harvard T.H. Chan School of Public Health.
We are incredibly proud of her achievement and grateful for her contributions to our transplant research program at @BIDMCTransplant @Harvard. A testament to the impact of the Innovative Research Initiative (IRI) Fellowship @IRI_program in developing the next generation of academic surgeon-scientists.
#HarvardChan #MPH #TransplantResearch #BIDMC #AcademicSurgery #ResearchFellowship
@BIDMCSurgery @BIDMChealth @BIDMC_CancerCtr @HarvardChanSPH @harvardmed @ASTSChimera @AHPBA @IHPBA – at Boston, MA
Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results: nejm.org/doi/full/10.1056/NE…
Editorial: Left Atrial Appendage Closure — Another Overused Method in Cardiology? nejm.org/doi/full/10.1056/NE…
Max Guarda, MD retweeted
Presented at #AHA25:
In a meta-analysis of 17,801 patients with myocardial infarction and preserved LVEF (≥50%), beta-blockers did not reduce death, MI, or heart failure over a median 3.6 years of follow-up. Full results: nej.md/43U5Ppo
@AHAScience
Max Guarda, MD retweeted
Hello #MedTwitter!
I’m Isabella, an IMG from Dominican Republic🇩🇴, working as a researcher @MayoClinic applying to #InternalMedicine this #Match2026
Outside of work, I love pilates and barre workouts🧦, specialty coffee☕️, and spending time outdoors🏃🏻♀️🚴🏻♀️🏝️
Let’s connect!
Max Guarda, MD retweeted
For the seventh consecutive year, Mayo Clinic is ranked No. 1 on @Newsweek’s World’s Best Hospitals 2025 list. mayocl.in/4hU17Ny
Max Guarda, MD retweeted
Thrilled to share that our abstract has been accepted for poster presentation at ACP national conference 2025. #ACPNational
Grateful for the mentorship of @drSandeepPagali and @RobMcbane and 2 sensational research teams.
Honored for this opportunity!!!
Max Guarda, MD retweeted
🚨 Breaking down the REGENCY trial 🚨
A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️
Max Guarda, MD retweeted
NEW—Safety of CAR T-cell therapy for cancer in pre-existing autoimmune or inflammatory disease: a retrospective comparative cohort study thelancet.com/journals/lanrh…
Max Guarda, MD retweeted
Congratulations to Dr. Alí Duarte-García, MD, MS @AliDuarteMD for receiving the 2024 Mary Betty Stevens, MD, Young Investigator Prize.
Dr. Duarte has made important contributions to understanding the epidemiology of systemic lupus erythematosus and antiphospholipid syndrome.
Alí, on behalf of my colleagues #MayoClinicRheumatology, we are incredibly proud of you and your accomplishments!
@LupusOrg
@MayoClinic
@ACRheum
@AshimaMakol @MdWarrington @MyasoedovaElena @CrowsonCindy
Max Guarda, MD retweeted
Congratulations to the 2024 ACR/ARP award recipients! We are especially proud of our colleagues @MayoClinic:
⭐️Cornelia (Connie) Weyand, MD, PhD
ACR 2024 Distinguished Basic/Translational Investigator Award
⭐️Cynthia (Cindy) S. Crowson, PhD
ARP 2024 Distinguished Scholar Award
#MayoClinicRheumatology
@AshimaMakol @MdWarrington @AliDuarteMD @MyasoedovaElena @CrowsonCindy @Dr_Vijay_Shah @KronzerMD
Max Guarda, MD retweeted
Take a look to the newest work by LUMEN 💡lab about delays in specialized care and diagnosis among patients with lupus- led by @lain_sanchez and @AliDuarteMD - acrjournals.onlinelibrary.wi…
Max Guarda, MD retweeted
Masterful #CVgrandrounds by #DrCasanegra @MayoClinicCV on "Failure of #AC" - is clot new? Is patient taking med? Look at treatment inherent vs patient inherent factors. No magic bullet for treatment. @RobMcbane @NicholeBrunton @SVM_tweets @PVDCouncil @ACCinTouch
Max Guarda, MD retweeted
Hi y’all!
I’m SO PSYCHED to be applying #psychiatry in the #match2025
I’m particularly passionate about interventional psychiatry, especially TMS.
In my free time, I can be found acting in local plays or dancing a mean Irish jig!
Best of luck to all applying this cycle! ☘️
Max Guarda, MD retweeted
Hi there! I’m Bernardita, MD from Chile🇨🇱, Research Fellow at @CleClinicUro applying Urology.
Eager to learn from my attendings, co-residents, nurses, and my patients. You can find me drawing on my iPad, reading, or hanging out with friends.
#uromatch #UroSoMe #Match2025
Max Guarda, MD retweeted
Why I love working at @MayoClinic:
10 AM – Incidental PE on CT, asymptomatic.
11 AM – Labs done.
12 PM – Patient gets lunch.
1 PM – Thrombophilia clinic, Lovenox shot.
2 PM – Rheum clinic with me.
3 PM – DOAC ready at Mayo Pharmacy.
Seamless, coordinated care at its best!
Max Guarda, MD retweeted
Comprehensive review of Intermediate-Risk #PE led by @NicholeBrunton with @MayoClinicCV @MayoPCCM teamwork! Our proposed algorithm for management below. @PERTConsortium @SVM_tweets @ACCinTouch @PVDCouncil
🔥 Editor’s Choice and Highly Viewed Paper
Risk Stratification and Management of Intermediate-Risk Acute Pulmonary Embolism mdpi.com/2623690
🧑⚕️by @stanhenkin et al. @NicholeBrunton
🎯Views 11532, Citations 3
@MediPharma_MDPI
#mdpijcm #MedTwitter #PulmonaryEmbolism #Cardio
Max Guarda, MD retweeted
Membranous nephropathy (MN) can occur in the transplant kidney as recurrent or de novo MN.
Recurrent MN is often PLA2R+
De novo MN is PLA2R-negative & often associated with antibody-mediated rejection.
The target antigen is unknown
FAT1 is the antigen! kidney-international.org/art…
Max Guarda, MD retweeted
Sharing our latest work with @MdWarrington in @ARD_BMJ! We used @SomaLogic proteomics to identify blood protein patterns in active and inactive Giant Cell Arteritis. Sights are now set to develop and validate ML-based multiplex biomarker panels for GCA!🚀
ard.bmj.com/content/early/20…
Max Guarda, MD retweeted
Dexmedetomidine made a promising splash when it arrived into the scene. Now that we’ve had some time to get to know it, its uses as a sedative agent are… well… disappointing. This paper illustrates why. 🎩 tip to the authors.
eddyjoemd.com/foamed/




































